Beta Bionics (NASDAQ:BBNX) Insider Sells $58,300.00 in Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mike Mensinger sold 2,650 shares of the firm’s stock in a transaction dated Tuesday, October 27th. The stock was sold at an average price of $22.00, for a total value of $58,300.00. Following the completion of the transaction, the insider directly owned 174,740 shares in the company, valued at $3,844,280. This trade represents a 1.49% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Mike Mensinger also recently made the following trade(s):

• On Wednesday, September 16th, Mike Mensinger sold 2,650 shares of Beta Bionics stock. The shares were sold at an average price of $22.00, for a total value of $58,300.00.
• On Wednesday, September 2nd, Mike Mensinger sold 4,375 shares of Beta Bionics stock. The shares were sold at an average price of $19.11, for a total value of $83,606.25.

Beta Bionics Trading Down 4.7%

Beta Bionics stock opened at $16.75 on Friday. The firm has a 50 day moving average of $19.11 and a 200 day moving average of $14.89. The firm has a market capitalization of $910.70 million, a price-to-earnings ratio of -9.10 and a beta of 3.39. Beta Bionics, Inc. has a 12-month low of $8.80 and a 12-month high of $32.71.

Beta Bionics (NASDAQ:BBNX) last released its earnings results on Tuesday, October 27th. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.01. Beta Bionics had a negative net margin of 65.31% and a negative return on equity of 27.33%. The company had revenue of $35.51 million for the quarter. On average, analysts predict that Beta Bionics, Inc. will post -2.03 EPS for the current year.

More Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Quarterly results slightly beat expectations. Beta Bionics reported a third-quarter loss of $0.52 per share, better than the $0.53 consensus estimate, while revenue of $35.51 million exceeded analysts’ expectations of approximately $34.7 million. The company also updated its 2026 guidance, although details were not provided. Beta Bionics third-quarter results
• Positive Sentiment: Analyst sentiment remains generally favorable. Stifel Nicolaus maintained a Buy rating, and several firms have raised price targets. MarketBeat data shows a Moderate Buy consensus and an average target of $23.69, above the recent trading level.
• Neutral Sentiment: Institutional ownership news was mixed but included notable purchases. BlackRock, Bank of America and other investment firms recently initiated or increased positions in Beta Bionics. Such activity may provide some support, but the reported purchases largely reflect earlier quarters rather than a new catalyst.
• Neutral Sentiment: Insiders continued to sell relatively small portions of their holdings. Director Mark Hopman sold 821 shares for about $16,420, while insider Mike Mensinger sold 2,650 shares for approximately $58,300. Both retained substantial positions, limiting the significance of the transactions, though repeated insider selling can weigh on investor sentiment. SEC insider filing
• Negative Sentiment: Multiple law firms reiterated a securities class-action deadline of November 3, 2026. The lawsuit covers investors who purchased BBNX securities from July 30, 2025, through February 24, 2026. The unusually large number of investor-law-firm notices increases legal, reputational and potential financial risks for Beta Bionics.
• Negative Sentiment: The allegations center on FDA compliance and iLet safety disclosures. Notices allege that Beta Bionics did not fully disclose information related to an FDA warning, quality-system issues and more than 18,000 iLet complaints, including potentially serious hypoglycemia incidents. These claims have not been proven, but possible litigation costs, regulatory action or additional product concerns could pressure the stock. Beta Bionics securities class action notice
• Negative Sentiment: Execution risks could cloud future growth. The company has disclosed challenges associated with the commercial launch of its next-generation Mint patch pump, adding uncertainty to its growth outlook.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Wall Street Zen cut shares of Beta Bionics from a “hold” rating to a “strong sell” rating in a research note on Saturday. Wells Fargo & Company began coverage on shares of Beta Bionics in a report on Wednesday, September 23rd. They issued an “overweight” rating and a $28.00 target price for the company. The Goldman Sachs Group increased their price target on Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. TD Cowen raised their price target on Beta Bionics from $18.00 to $21.00 and gave the company a “hold” rating in a report on Wednesday. Finally, William Blair initiated coverage on Beta Bionics in a research report on Friday, August 21st. They issued a “market perform” rating on the stock. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $23.69.

Institutional Investors Weigh In On Beta Bionics

A number of institutional investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc purchased a new position in shares of Beta Bionics in the second quarter worth $62,000. The Manufacturers Life Insurance Company bought a new position in shares of Beta Bionics during the second quarter worth $172,000. Ieq Capital LLC purchased a new position in Beta Bionics during the second quarter valued at $229,000. Quantbot Technologies LP purchased a new position in Beta Bionics during the second quarter valued at $264,000. Finally, Man Group plc purchased a new position in Beta Bionics during the second quarter valued at $419,000.

Beta Bionics Company Profile

Beta Bionics, Inc (NASDAQ: BBNX) is a medical technology company focused on developing and commercializing automated insulin-delivery systems for people with insulin-dependent diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with limited user input.

The iLet Bionic Pancreas combines a wearable insulin pump with continuous glucose monitoring technology and adaptive dosing algorithms. The system is designed to automatically adjust insulin delivery based on an individual’s glucose readings and requires users to provide relatively simple meal announcements rather than calculate precise carbohydrate amounts.